Department of Medical Oncology and Therapeutics Research, City of Hope and Beckman Research Institute, 1500 E. Duarte Rd., MOB 1001, Duarte, CA 91010, USA.
Cancer Lett. 2012 Aug 28;321(2):101-9. doi: 10.1016/j.canlet.2012.01.041. Epub 2012 Feb 3.
With the approval of the antiangiogenic antibody bevacizumab in non-small cell lung cancer (NSCLC) and other malignancies, the tumor vasculature has emerged as a worthwhile therapeutic target. Second-line therapies have the potential to improve overall survival and quality of life over best supportive care alone. Accordingly, phase II and phase III studies are actively evaluating antiangiogenic treatments in the second-line setting in NSCLC, and results are awaited. Such therapies include antiangiogenic antibodies, small molecule inhibitors, and vascular-disrupting agents. This review will present the current landscape of angiogenesis inhibition in NSCLC, focusing on use as second-line therapy.
随着抗血管生成抗体贝伐珠单抗在非小细胞肺癌（NSCLC）和其他恶性肿瘤中的批准，肿瘤血管已成为一个有价值的治疗靶点。二线治疗有可能改善总生存期和生活质量，而不仅仅是最佳支持治疗。因此，正在积极评估二线治疗 NSCLC 中的抗血管生成治疗的 II 期和 III 期研究，结果正在等待中。此类疗法包括抗血管生成抗体、小分子抑制剂和血管破坏剂。这篇综述将介绍 NSCLC 中血管生成抑制的现状，重点关注二线治疗的应用。
